Publication | Open Access

Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer

Breast OncologyOncologyMedicineBreast CancerFirst-line TreatmentAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyMolecular Oncology